Adverse cutaneous reactions to mood stabilizers

American Journal of Clinical Dermatology

Volumn 4, Issue 1, 2003, Pages 21-30

  Warnock, Julia K ^a   Morris, David W ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; BACITRACIN; BENZOYL PEROXIDE; CARBAMAZEPINE; CORTICOSTEROID; GABAPENTIN; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; LAMOTRIGINE; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PSYCHOTROPIC AGENT; SELENIUM; SULFADIAZINE SILVER; TOPIRAMATE; TRIAMCINOLONE; VALPROIC ACID; ZINC;

ACNE; ALOPECIA; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; BLOOD TOXICITY; CORTICOSTEROID THERAPY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; EOSINOPHILIA; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; FOLLICULITIS; HIRSUTISM; HUMAN; HYPERHIDROSIS; LEUKODERMA; LICHENOID ERUPTION; LUPUS ERYTHEMATOSUS; LYMPHADENOPATHY; LYMPHOCYTOSIS; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUSTULOSIS; RASH; REVIEW; RISK BENEFIT ANALYSIS; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN EDEMA; SKIN MANIFESTATION; SKIN PIGMENTATION; SKIN ULCER; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

DRUG ERUPTIONS; HUMANS; PSYCHOTROPIC DRUGS;

EID: 0037235198     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304010-00003     Document Type: Review

References (87)

1. Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002; 3 (9): 629-36
2. Culy CR, Goa KL. Lamotrigine: a review of its use in childhood epilepsy. Paediatr Drugs 2000 Jul; 2 (4): 299-330
3. Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf 2000 Apr; 22 (4): 303-12
4. Schaub N, Bircher AJ. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000 Feb; 55 (2): 191-3
5. Yalcin B, Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 2000 Nov: 43 (5 Pt 2): 898-9
6. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999 Jul; 40 (7): 985-91
7. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 3939: S22-6
8. Page RL, O'Neil MG, Yarbrough DR, et al. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998 Mar; 18 (2): 392-8
9. Sachs B, Ronnau AC, von Schmiedeberg S, et al. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997; 195 (1): 60-4
10. Li LM, Russo M, O'Donoghue MF, et al. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr 1996 Mar; 54 (1): 47-9
11. Troost RJ, Van Parys JA, Hooijkaas H, et al. Allergy to carbamazepine: parallel in vivo and in vitro detection. Epilepsia I996 Nov; 37 (11): 1093-9
12. Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35 Suppl. 3: S23-5
13. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993 Jan; 34 (1): 163-5
14. Medical Economics staff, editors. Physician's desk reference. 55th ed. Montvale (NJ): Medical Economics, 2001
15. Perry PJ, Alexander B, Liskow BI. Psychotropic drug handbook. 7th ed. Washington, DC: American Psychiatric Press, 1997
16. Welykyj S, Gradini R, Nakao J, et al. Carbamazepine-induced eruption histologically mimicking mycosis fungoides. J Cutan Pathol 1990 Apr; 17 (2): 111-6
17. Roberts DL, Marks R. Skin reactions to carbamazepine. Arch Dermatol 1981 May; 117 (5): 273-5
18. Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997 Aug: 24 (3): 245-9
19. Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993 Nov; 29 (5): 254-7
20. Konishi T, Naganuma Y, Hongo K, et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993 Jul; 152 (7): 605-8
21. Atkin SL, McKenzie TM, Stevenson CJ. Carbamazepine-induced lichenoid eruption. Clin Exp Dermatol 1990 Sep; 15 (5): 382-3
22. Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color atlas and synopsis of clinical dermatology: common and serious diseases. 4th ed. New York: McGraw-Hill, 2001
23. Brenner S, Wolf R, Landau M, et al. Psoriasiform eruption induced by anticonvulsants. Isr J Med Sci 1994 Apr; 30 (4): 283-6
24. Gebauer K, Holgate C, Navaratnam A. Toxic pustuloderma: a drug induced pustulating glandular fever-like syndrome. Australas J Dermatol 1990; 31 (2): 89-93
25. Commens CA, Fischer GO. Toxic pustuloderma following carbamazepine therapy. Arch Dermatol 1988 Feb; 124 (2): 178-9
26. Dooley J, Camfield P, Gordon K, et al. Lamotrigine-induced rash in children. Neurology 1996 Jan; 46 (1): 240-2
27. Wong IC, Mawer GE, Sander JW. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001 Feb; 42 (2): 237-44
28. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999 Oct; 33 (10): 1037-42
29. Richens A. Safety of lamotrigine. Epilepsia 1994: 3535: S37-40
30. Sander JW, Trevisol-Bittencourt PC, Hart YM, et al. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990 Dec; 7 (3): 226-9
31. Srebrnik A, Hes JP, Brenner S. Adverse cutaneous reactions to psychotropic drugs. Acta Derm Venereol 1991; 158: 3-12
32. Ghadirian AM, Lalinec-Michaud M. Report of a patient with lithium-related alopecia and psoriasis. J Clin Psychiatry 1986 Apr; 47 (4): 212-3
33. Natsch S, Hekster YA, Keyser A, et al. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 1997 Oct; 17 (4): 228-40
34. Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995 Oct; 50 (4): 691-713
35. Srebrnik A, Bar-Nathan EA, Ilie B, et al. Vaginal ulcerations due to lithium carbonate therapy. Cutis 1991 Jul; 48 (1): 65-6
36. Hogan DJ, Murphy F, Burgess WR, et al. Lichenoid stomatitis associated with lithium carbonate. J Am Acad Dermatol 1985 Aug; 13 (2 Pt 1): 243-6
37. Bublin JG, Thompson DF. Drug-induced hair color changes. J Clin Pharm Ther 1992 Oct; 17 (5): 297-302
38. Bittencourt PR. Valproic acid, curly hair and weight gain. Arq Neuropsiquiatr 1986 Mar; 44 (1): 78-81
39. Gupta AK. 'Perming' effects associated with chronic valproate therapy. Br J Clin Pract 1988 Feb; 42 (2): 75-7
40. Jeavons PM, Clark JE, Harding GF. Valproate and curly hair [letter]. Lancet 1977 Feb 12; I (8007): 359
41. Miranda-Romero A, Perez-Oliva N, Aragoneses H, et al. Carbamazepine hypersensitivity syndrome mimicking mycosis fungoides. Cutis 2001 Jan; 67 (1): 47-51
42. Lombardi SM, Girelli DG, Corrocher R. Severe multisystemic hypersensitivity reaction to carbamazepine including dyserythropoietic anemia. Ann Pharmacother 1999 May; 33 (5): 571-5
43. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39 Suppl. 7: S3-7
44. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997 Aug; 49 (2): 542-6
45. Troost RJ, Oranje AP, Lijnen RL, et al. Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Pediatr Dermatol 1996 Jul; 13 (4): 316-20
46. Okuyama R, Ichinohasama R, Tagami H. Carbamazepine induced erythroderma with systemic lymphadenopathy. J Dermatol 1996 Jul; 23 (7): 489-94
47. De Vriese AS, Philippe J, Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995 May; 74 (3): 144-51
48. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995 Nov 27; 155 (21): 2285-90
49. Scerri L, Shall L, Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome: pathogenic and diagnostic considerations. Clin Exp Dermatol 1993 Nov; 18 (6): 540-2
50. Horneff G, Lenard HG, Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics 1992 Oct; 23 (5): 272-5
51. Robbie MJ, Scurry JP, Stevenson P. Carbamazepine-induced severe systemic hypersensitivity reaction with eosinophilia. Drug Intell Clin Pharm 1988 Oct; 22 (10): 783-4
52. Cullinan SA, Bower GC. Acute pulmonary hypersensitivity to carbamazepine. Chest 1975 Oct; 68 (4): 580-1
53. Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol 1993 Feb; 16 (1): 19-29
54. Friedmann PS, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994 May; 130 (5): 598-604
55. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study: Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999 Jun 26; 353 (9171): 2190-4
56. Leenutaphong V, Sivayathorn A, Suthipinittharm P, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993 Jun; 32 (6): 428-31
57. DeToledo JC, Minagar A, Lowe MR, et al. Skin eruption with gabapentin in a patient with repeated AED-induced Stevens-Johnson's syndrome. Ther Drug Monit 1999 Feb; 21 (1): 137-8
58. Schwartz RA. Toxic epidermal necrolysis. Cutis 1997 Mar; 59 (3): 123-8
59. Breathnach SM, McGibbon DH, Ive FA, et al. Carbamazepine ('Tegretol') and toxic epidermal necrolysis: report of three cases with histopathological observations. Clin Exp Dermatol 1982 Nov; 7 (6): 585-91
60. Schaub N, Bircher AJ. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000 Feb; 55 (2): 191-3
61. Iannetti P, Raucci U, Zuccaro P, et al. Lamotrigine hypersensitivity in childhood epilepsy. Epilepsia 1998 May; 39 (5): 502-7
62. Sarzi-Puttini P, Panni B, Cazzola M, et al. Lamotrigine-induced lupus. Lupus 2000; 9 (7): 555-7
63. Fogh K, Mai J. Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). Seizure 1997 Feb; 6 (1): 63-5
64. Chaffin JJ, Davis SM. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother 1997 Jun; 31 (6): 720-3
65. Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995 Nov; 33 (11): 595-7
66. Faught E, Morris G. Jacobson M, et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects: postmarketing antiepileptic drug survey (PADS) group. Epilepsia 1999; 40 (8): 1135-40
67. Meinhold JM, West DP, Gurwich E, et al. Cutaneous reaction to lithium carbonate: a case report. J Clin Psychiatry 1980 Nov; 41 (11): 395-6
68. Wakelin SH, Lipscombe T, Orton DI, et al. Lithium-induced follicular hyperkeratosis. Clin Exp Dermatol 1996 Jul; 21 (4): 296-8
69. Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998 Apr; 18 (4): 281-96
70. Harth Y, Rapoport M. Photosensitivity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996 Apr; 14 (4): 252-9
71. Epstein JH, Wintroub BU. Photosensitivity due to drugs. Drugs 1985; 30 (1): 42-57
72. Warnock JK, Knesevich JW. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988; 145: 425-30
73. Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999 Oct; 60 (10): 714-25
74. Benning TL, McCormack KM, Ingram P, et al. Microprobe analysis of chlorpromazine pigmentation. Arch Dermatol 1988; 124 (10): 1541-4
75. Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996 Jul; 14 (3): 503-8
76. Stroud JD. Drug-induced alopecia. Semin Dermatol 1985; 4: 29-34
77. Warnock JK. Psychotropic medication and drug-related alopecia. Psychosomatics 1991 Spr; 32 (2): 149-52
78. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85
79. Herbert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 2001; 62 Suppl. 14: 22-6
80. Yoon Y, Jagoda A. New antiepileptic drugs and preparations. Emerg Med Clin North Am 2000; 18: 755-65
81. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 Oct; 282 (5388): 490-3
82. Habif TP. Clinical dermatology. 3rd ed. Chicago (IL): Mosby-Year Book, 1996
83. Morkunas AR, Miller MB. Anticonvulsant hypersensitivity syndrome. Crit Care Clin 1997; 13: 727-39
84. Knowles SR Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999 Dec; 21 (6): 489-501
85. Manders SM. Serious and life-threatening drug eruptions. Am Fam Physician 1995 Jun; 51 (8): 1865-72
86. American Academy of Dermatology. Guidelines of care for cutaneous adverse drug reactions. J Am Acad Dermatol 1996; 35: 458-61
87. Warnock JK, Morris DW. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002; 3 (5): 329-39